Loading…
← CockpitCompetitor Analysis › 002393.SZ Tianjin Lisheng Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Tianjin Lisheng Pharmaceutical Co., Ltd. Class A002393.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major
Momentum neutral 46
Mkt cap
$557M
US dollars, full cap
Free float
45%
of shares outstanding
$/day
$4.21M
20-day average traded
Fwd P/E
9.0×
forward earnings
ROIC−WACC
-1.5 pp
WACC 6.1%
Hurdle
-10 pp
Req g minus delivered
Next earnings
121 days
19 Mar 2027
Close · CNYCN¥12.12
1D-1.5%
1W-5.0%
1M-10.8%
3M-19.1%
6M-24.0%
YTD-33.0%
1Y-32.0%
ATR %2.5%
52w lowhigh40.4% off high

What Tianjin Lisheng Pharmaceutical does

Employees: 1,605

Tianjin Lisheng Pharmaceutical at a glance

Size Tianjin Lisheng Pharmaceutical (002393.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $557M, the 3431st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥12.12 on 18 Nov 2026.

Performance Over six months the shares fell 24.0%, against -19.8% for the median peer and -20.0% for the China market (cap-weighted) — 8th lowest of 20 in its peer set.

Growth Revenue fell 2.7% over the last twelve months (peer median +3.5%); the operating margin is 6.6% (peer median 5.1%).

Valuation It trades at 9.0× forward earnings against a peer median of 11.3× (2nd cheapest of 10).

Price implies For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is -10 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 1.5 points below its cost of capital (6.1% WACC).

Next results Next results expected around 19 Mar 2027 (exchange calendar; dates can move).

Relative performance

809010011021 May 202621 Aug 202618 Nov 2026002393.SZ 78Peer median 77
Six months, rebased to 100: Tianjin Lisheng Pharmaceutical against the median of its 20 peers (local-currency closes).

Tianjin Lisheng Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.27BCN¥1.38BCN¥1.32BCN¥1.14BCN¥1.13B
Revenue growth—+4%+16%+1%—
Gross profitCN¥686MCN¥732MCN¥697MCN¥646MCN¥620M
EBITDAn/aCN¥173MCN¥148MCN¥180MCN¥124M
Net incomeCN¥124MCN¥416MCN¥185MCN¥362MCN¥93.6M
Free cash flowCN¥244MCN¥414MCN¥74.9MCN¥148MCN¥311M
Capital expenditureCN¥41.0MCN¥37.5MCN¥53.8MCN¥61.7MCN¥40.9M
Total debtCN¥46.0MCN¥174MCN¥113MCN¥63.0MCN¥66.1M

Quarterly statements and history in the cockpit →

Tianjin Lisheng Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%-40%-20%0%ACRS003850600568ZVRA4559688356002688ENTXALMSMOREPENLABSENORES22562157603439CGEM002393.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Tianjin Lisheng Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

-25%0%+25%+50%+75%20×40×003850ZVRA4559688356002688SENORES36132157603439002393.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Tianjin Lisheng Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%003850ZVRA45596883560026883613603439000919002393.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Tianjin Lisheng Pharmaceutical is the large dot.

Tianjin Lisheng Pharmaceutical competitors and peer comparison

How Tianjin Lisheng Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Tianjin Lisheng Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure002393.SZPeer medianRank in peer set
1-month return-10.8%-11.4%10th highest of 21
6-month return-24.0%-19.8%8th lowest of 20
Distance from 52-week high-40.4%-42.9%8th highest of 21
Revenue growth (TTM)-2.7%+3.5%9th lowest of 19
Operating margin6.6%5.1%8th highest of 18
Forward P/E9.0×11.3×2nd cheapest of 10
Growth the price implies (Req g, 7 yrs)-5.8%-1.0%3rd least demanding of 9
Growth delivered (Del g)+4.1%+11.1%2nd lowest of 9
Hurdle (Req g minus delivered)-9.9 pp-12.2 pp5th least demanding of 9
ROIC minus cost of capital-1.5 pp-3.6 pp7th highest of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Tianjin Lisheng Pharmaceutical 002393.SZChina$557M-24%-3%7%9.0×-5.8%+4.1%
Aclaris Therapeutics ACRSUnited States$555M-23%-59%-1,412%n/an/an/a
Boryung 003850.KSSouth Korea$554M-13%+6%6%11.3×-3.1%+12.6%
Zhong Zhu Healthcare 600568.SSChina$562M-22%-6%-34%n/an/an/a
Zevra Therapeutics ZVRAUnited States$552M-9%+75%31%11.3×-4.9%+51.6%
Zeria Pharmaceutical 4559.TJapan$552M-12%+12%15%9.6×-12.3%+11.1%
Jenkem Technology 688356.SSChina$563M-30%+52%11%30.2×36.4%+11.2%
Jinhe Biotechnology 002688.SZChina$550M-19%+7%5%8.9×1.0%+9.7%
Entera Bio ENTXUnited States$568M+163%-100%n/an/an/an/a
Alumis ALMSUnited States$569M-80%-67%-5,375%n/an/an/a
Morepen Laboratories MOREPENLAB.NSIndia$542M+121%+30%11%n/an/an/a
Senores Pharmaceuticals SENORES.NSIndia$538M+3%+40%24%32.2×n/an/a
Beijing Tong Ren Tang Chinese Medicine 3613.HKHong Kong$577M-26%-21%32%10.2×-15.4%+2.8%
Abbisko Cayman 2256.HKHong Kong$578M-39%-83%-520%n/an/an/a
Oneness Biotech 4743.TWOTaiwan$580M-13%+19%-589%n/an/an/a
Lepu Biopharma 2157.HKHong Kong$580M-43%+47%7%53.6×n/an/a
Chimin Health Management 603222.SSChina$533M-31%+1%-28%n/an/an/a
GuiZhou SanLi Pharmaceutical 603439.SSChina$583M-20%-6%5%26.8×20.9%+21.9%
Cullinan Therapeutics CGEMUnited States$585M-37%n/an/an/an/an/a
Electra Therapeutics ETRAUnited States$530Mn/an/an/an/an/an/a
Jinling Pharmaceutical 000919.SZChina$529M-15%-8%1%n/a2.4%+5.0%

Questions

Which companies are Tianjin Lisheng Pharmaceutical's closest peers?
The cockpit's peer set: Aclaris Therapeutics (ACRS), Boryung (003850.KS), Zhong Zhu Healthcare (600568.SS), Zevra Therapeutics (ZVRA), Zeria Pharmaceutical (4559.T), Jenkem Technology (688356.SS), Jinhe Biotechnology (002688.SZ), Entera Bio (ENTX).
Is Tianjin Lisheng Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 9.0× against a peer median of 11.3×, 2nd cheapest of 10 in its peer set. For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is -10 pp: the price already allows for a slowdown.
How has Tianjin Lisheng Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -24.0% against -19.8% for the median peer; over one year -32.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.